SureTrader
Home > Boards > US OTC > Medical - Drugs >

Creative Medical Technology Holdings, Inc. (CELZ)

CELZ RSS Feed
Add CELZ Price Alert      Hide Sticky   Hide Intro
Moderator: Dynamic_Star, Werbe
Search This Board: 
Last Post: 2/19/2018 8:21:05 AM - Followers: 44 - Board type: Free - Posts Today: 1


 

About Us


CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is a clinical-stage biotechnology company focused on Urology and Neurology using stem cell treatments.  Through our own research and collaborations with leading academic institutions, CMT has acquired a groundbreaking stem cell (Amniostem), developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction, launched a 40-patient trial for ED at UCLA and are breaking new ground for treating stroke using our newly acquired amniotic fluid-based stem cell.  Our team consists of leading international researchers in regenerative medicine.  Our “science-first” approach to treatments ensures that all of our treatments are proven to be both safe and effective.



Contact Info


2017 W Peoria Avenue
Phoenix, AZ 85029
Phone: (602) 680-7439
Website:
http://www.creativemedicaltechnology.com/




Share Structure Information As Of 01/31/2018
 

 
Authorized Shares - 600,000,000

Outstanding Shares - 137,678,812
 

 






Company News
 

Stem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism
PHOENIX, Dec. 20, 2017
 

PHOENIX, Dec. 20, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides the following discussion on a recent US News and World Report article[1] addressing advances of adult stem cells and its own patented stem cell technologies.

Stem cells are broadly categorized into "embryonic" and "adult" stem cells.  Embryonic stem cells are derived from fertilized eggs and hold potential to generate every major tissue in the body.  Unfortunately, embryonic stem cells are difficult to control due to their very immature state.  This limits their ability to be used in patients, which has accounted for a lack of commercial success.  In contrast, adult stem cells, which are classified as every type of stem cell that is not embryonic, are the basis of the technology of the two publicly traded biotech companies referenced in the article, Mesoblast and Athersys.  Currently, Mesoblast is developing stem cells based on bone marrow stem cells from donors, primarily for treating heart failure, which is in the most advanced phases of clinical trials, termed Phase III.  Additionally, Athersys is also using bone marrow derived stem cells from donors, primarily for use in stroke, which is also in Phase III clinical trials.

"We at Creative Medical Technologies are encouraged by this promising article that highlights the important advances being made by adult stem cell companies in addressing the significant unmet medical needs in degenerative conditions such as stroke and heart failure," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings.   "For the past 7 years, we have been working on developing two types of adult stem cell therapies which are protected by issued US patents."

Our first type of technology is based on a more immediate commercialization, these therapies use the patient's own unexpanded and minimally manipulated stem cells, termed autologous stem cells, that can be rapidly implemented because of the long safety record of this type of procedure.  Our CaverstemTM procedure, involves using the patient's own bone marrow derived stem cells to treat drug-resistant erectile dysfunction. This clinically tried procedure is already being performed by doctors on the West Coast. 

Our second autologous bone marrow stem cell procedure for the treatment of degenerative disc disease, termed StemSpine™, is in the process of commercialization.  Our second type of technology is a "universal donor" stem cell that is similar to stem cells developed by Athersys and Mesoblast.  In contrast to other universal donor stem cell types, the stem cell developed by Creative Medical Technology Holdings, Inc., termed "AmnioStemTM is derived from amniotic fluid, which possesses a higher ability to regenerate tissues as compared to other stem cell types.  Our AmnioStemTM, universal donor stem cell is being developed as a treatment for stroke, with an FDA Investigational New Drug Application (IND) filing planned to initiate clinical trials.

"I am very impressed with the speed, agility, and precision that the team at Creative Medical Technology Holdings has displayed in advancing both autologous and allogeneic stem cell therapies," said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Director of the Neuroscience Research Center at the Pacific Neuroscience Institute and Member of Creative Medical Technology Holdings, Inc. Scientific Advisory Board. "I look forward to working with the company in advancing its adult stem cell therapy products, which aim to address numerous unmet medical needs."


https://money.usnews.com/investing/news/articles/2017-12-18/tiny-stem-cell-companies-close-in-on-major-heart-disease-goals
 




"Urologist to the Stars" Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem™ Stem Cell Procedure for Drug Refractory Erectile Dysfunction
PHOENIX, and LOS ANGELES, Dec. 18, 2017

 

PHOENIX, and LOS ANGELES, Dec. 18, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today initiation of patient treatments using its patented Caverstem™ procedure by Dr.  Alexander Gershman.  

Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the procedure, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient within less than an hour. 

"There is much excitement about stem cells revolutionizing many aspects of medicine.  I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive," said Dr. Gershman. "Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA, support the safety and feasibility of the Caverstem™ procedure.  The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells.  By administering the patient's own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function."  

Creative Medical Health Technology Holdings is offering the Caverstem™ procedure to selected urologists in the USA, which qualify according to the Company's criteria.  Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

"We are pleased to have received such enthusiasm from one of the Opinion Leaders of the Urology community in the first 30 days of commercialization and anticipate similar responses as we expand our physician base throughout the United States" said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc.


https://www.prnewswire.com/news-releases/urologist-to-the-stars-dr-alexander-gershman-begins-treating-patients-with-patented-caverstem-stem-cell-procedure-for-drug-refractory-erectile-dysfunction-300572504.html


 



 

Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction
PHOENIX, Oct. 19, 2017

 

PHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB – CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure

The trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. An independent medical safety monitor was also appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction.  The goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.

"Based on establishment of safety of the CaverStem™ procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem™ procedure," said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.  "Amongst other top urologists, we have recruited a world-renowned urologist as a lead physician to roll-out the procedure. We anticipate that the procedure will be available to patients that meet the eligibility criteria within the next 60 days."

According to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.

"The CaverStem™ procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis," said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company.  "Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside."


https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-commercialization-of-patented-stem-cell-procedure-for-erectile-dysfunction-300539944.html


 



 

Creative Medical Technology Holdings Expands Stem Cell Therapeutic Platform by Entry into Field of Stroke and Neurodegeneration
PHOENIX, Oct. 16, 2017

 

PHOENIX, Oct. 16, 2017 /PRNewswire/ --  Creative Medical Technology Holdings (OTCQB: CELZ) announced today filing of a patent application using a combination of an FDA approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke.  The patent, entitled "Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy", covers the use of the patient's bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain types of strokes.  The Company has currently two issued patents using the patient's own bone marrow stem cells covering disc regeneration #9,598,673, and erectile dysfunction #8,372,797.  The Company has recently reported completion of enrollment in its clinical trial for erectile dysfunction. 

"Stroke represents one of those situations where the body's own stem cells leave the bone marrow, enter circulation, and attempt to heal the damaged brain areas.  It is documented that patients in which larger numbers of bone marrow stem cells enter circulation, have a better prognosis as compared to patients in which stroke induces a lower number of stem cells to enter circulation1," said Thomas Ichim, Ph.D, Chief Scientific Officer of Creative Medical Technology Holdings. "In the current patent we augment the naturally occurring approach by extracting stem cells from the bone marrow, placing them in circulation, and administering an FDA approved drug to enhance their activity.  We are particularly excited by the fact that this approach falls under the practice of medicine and does not require full clinical trials for commercialization."

Creative Medical Technology Holdings focuses on rapid commercialization-based approaches using the patient's own stem cells under the practice of medicine.

"Stroke is a devastating condition, which is estimated to represent an over $20 billion dollar annual market in the USA alone.  We are confident that our new approach to addressing stroke will provide a new tool in the hands of neurologists, which will allow for a 'natural-based' regenerative approach to this condition," said Timothy Warbington, President and Chief Executive Officer of the Company. "Given that we have been previously successful at having patents issued using autologous approaches, as well as our rapid entry into the clinic, we are excited to open up yet another market for our technology platform."



https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-expands-stem-cell-therapeutic-platform-by-entry-into-field-of-stroke-and-neurodegeneration-300536679.html


 



 

Creative Medical Technology Holdings Achieves 100% Patient Enrollment in CaverstemTM Clinical Trial for Stem Cell Treatment of Erectile Dysfunction
PHOENIX, Aug. 28, 2017

 

PHOENIX, Aug. 28, 2017 /PRNewswire/ -- Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM procedure to treat erectile dysfunction in patients who do not respond to currently available treatments. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

"The CaverstemTM procedure, which uses the patient's own bone marrow derived stem cells to induce arterial and venous regeneration, is an outpatient procedure able to be conducted by Urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.

The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA.

"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."

"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up. We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.


https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-achieves-100-patient-enrollment-in-caverstemtm-clinical-trial-for-stem-cell-treatment-of-erectile-dysfunction-300509805.html



 




Creative Medical Technology Holdings, Inc. Files Patent on AmnioStem™ Mediated Immune Reprogramming for Stroke
PHOENIX and SAN DIEGO, May 24, 2017

 

PHOENIX and SAN DIEGO, May 24, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the "Company") announced today the filing of a patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming immune cells of the stroke victim.

The patent application teaches ways of using the Company's patented AmnioStem™ allogeneic stem cell to 'educate' immune cells from stroke patients so as to reduce inflammation associated with stroke. By reducing inflammation, the Company hopes to develop novel means of increasing efficacy of therapeutic agents in stroke patients.

"We are highly enthusiastic with our current data, which seems to suggest that AmnioStem™cells are not only capable of inducing regeneration of injured brains, but also can be used to 'reprogram' immune system cells of patients in order to reduce inflammation that occurs subsequent to stroke," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Working together with immunologists, neurologists, and stem cell experts, we are fortunate to have a team that can attack the problem of stroke in a multidisciplinary manner."

It is known that the immune system contributes to the deterioration of brain functions after a stroke. For example, studies in the mouse model of stroke have shown that if certain immune cells are depleted, the neurological impact of a stroke is diminished.1 It is also known that part of the therapeutic activities of stem cells in a stroke are mediated by alterations of the immune system.2

"We are confident that the novel findings presented in the patent application will pave the way for using AmnioStemTM treated patient immune cells as a means of suppressing pathological responses, which is applicable not only to strokes, but to a wide variety of neuroinflammatory conditions including multiple sclerosis and traumatic brain injuries," said Thomas lchim, Ph.D., Chief Scientific Officer of Creative Medical Technology Holdings.

1 Belinga et al. Splenectomy following MCAO inhibits the TLR4-NF-KB signaling pathway and protects the brain from neurodegeneration in rats. J Neuroimmunol. 2016 Apr 15; 293:105-13
https://www.ncbi.nlm.nih.gov/pubmed/27049570
2 Cheng et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation.  Brain Res. 2015 Jan 12;1594:293-304.
https://www.ncbi.nlm.nih.gov/pubmed/?term=25449888


https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-inc-files-patent-on-amniostem-mediated-immune-reprogramming-for-stroke-300463435.html


 


Stem Cell Technologies
 

                                                                                                                                            


 


 

Scientific Advisory Board

 
Eric Duckers MD PhD
Dr. Duckers is currently Assistant Professor, Erasmus Medical Center, Head, Molecular Cardiology Laboratory, Erasmus Medical Center and Interventional Cardiologist, Erasmus Medical Center, Rotterdam, Netherlands.
 
Timothy Henry MD
Dr. Henry is currently the Director of Cardiology, Cedars-Sinai Heart Institute. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation.
 
Warren Sherman MD
Dr. Sherman is currently the Chief Medical Officer at Cardio 3 and was formerly Director of Cardiac Cell-Based Endovascular Therapies, Columbia University Medical Center and New York Presbyterian Hospital.
 
Masato Mitsuhashi MD PhD
Dr. Mitsuhashi is currently the Chief Technology Officer of Nanosomix. Dr. Mitsuhashi’s experience also includes Chief Scientific Officer at Hitachi Chemical Research Corporation.
 
 
 
SureTrader
CELZ
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
CELZ News: Current Report Filing (8-k) 02/01/2018 05:17:34 PM
CELZ News: Information Statement - All Other (definitive) (def 14c) 01/31/2018 06:09:53 AM
CELZ News: Information Statements (revised) (prer14c) 01/23/2018 04:56:14 PM
CELZ News: Current Report Filing (8-k) 01/16/2018 04:08:51 PM
CELZ News: Proxy Statement - Other Information (preliminary) (pre 14c) 01/12/2018 02:24:05 PM
PlusOneCoin Top Posts
#373   The news release dated 1/31/2018: chadpounder 02/16/18 03:24:01 PM
#374   Copy Paste That....I Dont Believe That Or It CashMoneyExpress 02/16/18 03:25:15 PM
#372     chadpounder 02/16/18 03:21:40 PM
PostSubject
#254  Sticky Note Share Structure Information As Of 01/31/2018 Werbe 02/15/18 11:46:35 PM
#158  Sticky Note CELZ = definition of a sleeper? They Werbe 02/03/18 02:48:28 PM
#418   That would be normal trading action on many stockstalk09 02/19/18 08:21:04 AM
#417   Yes, caps a great judge with real stocks/real Werbe 02/18/18 09:28:09 PM
#416   That's a damn low cap. I consider mijReswoh 02/18/18 09:22:48 PM
#415   I try 2 avoid estimates or evaluations myself Werbe 02/18/18 09:16:16 PM
#414   What do you have the market cap at mijReswoh 02/18/18 09:06:09 PM
#413   Yeah but better 4 us all right. Werbe 02/18/18 08:55:15 PM
#412   No trading tomorrow son.. devilfromscratch 02/18/18 08:51:55 PM
#411   Banking on their last PR saying they have JEck017 02/18/18 08:31:55 PM
#410   T-trades don’t automatically mean dilution Sniper_Trades1 02/18/18 08:23:34 PM
#409   .02 potential by eow Imarket13 02/18/18 05:24:54 PM
#408   Still expect a 2 can’t break but have JEck017 02/18/18 05:21:26 PM
#407   I know!... Hoping this settles at atleadt 10cents Imarket13 02/18/18 05:16:12 PM
#406   This was .50 just a year ago! er111a 02/18/18 04:17:31 PM
#405   With all this going on im shocked we Imarket13 02/18/18 03:26:36 PM
#404   They have multiple stem cell techs.. The Werbe 02/18/18 12:20:34 PM
#403   I’d expect it to break .015 Tuesday then LightandShadow 02/18/18 12:10:51 PM
#402   So I’m confused a bit. If they have Kcchas5022 02/18/18 11:25:16 AM
#401   Yeah, true upside here.. They have top Werbe 02/18/18 10:16:33 AM
#400   Looks like there might be some long-term potential Caveat Emptor 02/18/18 09:00:15 AM
#399   Awesome last couple days CELZ family.. Check Werbe 02/17/18 07:19:28 PM
#398   On tuesday? Or by eow Imarket13 02/17/18 11:42:33 AM
#397   I see it testing 2 cents the_stockoracle 02/17/18 11:25:20 AM
#396   Another nice day for CELZ. reaper247 02/17/18 12:10:21 AM
#395   Think we hit a nickel next week or Imarket13 02/16/18 07:52:03 PM
#394   Weeeee!!!!! PyschoNoobStock 02/16/18 06:25:39 PM
#393   Great couple of days here. Congrats to all, odiaz28 02/16/18 06:18:52 PM
#392   And a 4.5mil Giddycarol30 02/16/18 04:32:08 PM
#391   I’m was just thking the same.. Where’s WERB-eeee?? Giddycarol30 02/16/18 04:31:46 PM
#390   What do you all make of the T-trades BigB111 02/16/18 04:25:17 PM
#389   Nice 3 Mill slap EOD dannylc27 02/16/18 04:17:27 PM
#388   Have a blessed weekend y'all. See you on Dynamic_Star 02/16/18 04:02:57 PM
#387   .0118 would be better...waiting for those slaps ?? @WolfofWeedST 02/16/18 03:47:49 PM
#386   :-) I like that attitude. Good man Werbe 02/16/18 03:46:42 PM
#385   Good Point Dynamic... CELZ ! CashMoneyExpress 02/16/18 03:46:31 PM
#384   $CELZ is an OTC QB stock which will Dynamic_Star 02/16/18 03:43:42 PM
#383   You guys are feisty here. I kind chadpounder 02/16/18 03:39:51 PM
#382   Don’t be a Chad. cadfxguy 02/16/18 03:37:25 PM
#381   Well If That Is The Case Why Is CashMoneyExpress 02/16/18 03:36:49 PM
#380   Yes lol. Any funding needs 2 have Werbe 02/16/18 03:34:25 PM
#379   Most of the 600M current OS is restricted Dynamic_Star 02/16/18 03:32:16 PM
#378   I’ll be buying the last 5 mins the_stockoracle 02/16/18 03:32:11 PM
#377   Lol two epic runs in two days and Werbe 02/16/18 03:27:06 PM
#376   Sonprobably notnfor another week Imarket13 02/16/18 03:25:54 PM
#375   We shall see where it goes from here. chadpounder 02/16/18 03:25:47 PM
#374   Copy Paste That....I Dont Believe That Or It CashMoneyExpress 02/16/18 03:25:15 PM
#373   The news release dated 1/31/2018: chadpounder 02/16/18 03:24:01 PM
#372     chadpounder 02/16/18 03:21:40 PM
#371   I dont see that where did you see CashMoneyExpress 02/16/18 03:20:12 PM
#370   I would love to know what the OS chadpounder 02/16/18 03:20:10 PM
#369   I pulled the trigger because the O/S is PhenixBleu 02/16/18 03:17:52 PM
PostSubject